Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy
Author Information
Author(s): Hernyák Marcell, Tóth László Imre, Csiha Sára, Molnár Ágnes, Lőrincz Hajnalka, Paragh György, Harangi Mariann, Sztanek Ferenc
Primary Institution: University of Debrecen
Hypothesis
The study aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with alpha-lipoic acid.
Conclusion
Kallistatin could represent a potential new biomarker for assessing therapeutic response during alpha-lipoic acid treatment in patients with diabetic sensorimotor polyneuropathy.
Supporting Evidence
- Kallistatin levels significantly decreased after ALA treatment.
- Improvements in neuropathic symptoms correlated positively with changes in kallistatin levels.
- Changes in kallistatin levels were positively correlated with changes in oxLDL.
Takeaway
This study looked at how a treatment called alpha-lipoic acid affects a substance called kallistatin in people with diabetes and nerve problems. It found that kallistatin levels went down with treatment, which might help doctors understand how well the treatment is working.
Methodology
The study involved measuring serum concentrations of kallistatin and other markers in diabetic patients before and after six months of alpha-lipoic acid treatment.
Potential Biases
Potential biases may arise from the exclusion criteria and the specific patient population studied.
Limitations
The study's cross-sectional design limits the ability to establish causation, and the sample size may have influenced the significance of the findings.
Participant Demographics
54 patients with T2DM and DSPN (22 men and 32 women; mean age: 64.2 years).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website